Saturday, October 3, 2026

USD/CNH Went Down By Over 3% In The Last 21 Sessions

USD/CNH Went Down By Over 3% In The Last 21 Sessions

(VIANEWS) - USD/CNH (USDCNH) has been up by 3.89% for the last 21 sessions. At 14:15 EST on Sunday, 12 March, USD/CNH (USDCNH) is $6.93.

USD/CNH's yearly highs and lows, it's 0% down from its 52-week low and 0% down from its 52-week high.

News about

  • Usd/jpy sticks to boj-inspired gains, remains below 137.00 ahead of US NFP report. According to FXStreet on Friday, 10 March, "This, along with the latest US consumer inflation figures, due next Tuesday, will influence the Fed's rate-hike path, which will drive the USD and provide a fresh directional impetus to the USD/JPY Pair.", "Apart from this, some follow-through US Dollar selling contributes to keeping a lid on any further gains for the USD/JPY pair, at least for the time being. "
  • Usd/jpy falls to test daily lows near 135.80 after NFP. According to FXStreet on Friday, 10 March, "The USD/JPY dropped to levels sub 136.00 following the release of the US employment report. ", "The daily lows area in USD/JPY is being challenged at the moment, and a break lower could trigger an acceleration. "
  • Usd/jpy: A bigger retracement could be on the horizon – MUFG. According to FXStreet on Friday, 10 March, "USD/JPY has bounced on the back of the BoJ policy announcement but the developments in the US seem far more significant and given the US yield move, a bigger retracement in USD/JPY could be on the horizon."
  • Usd/jpy forecast: dollar has a pullback against yen - 10 March 2023. According to DailyForex on Friday, 10 March, "The USD/JPY has shown some weakness against the Japanese yen during Thursday's trading session, solidifying the idea of the ¥137.50-¥138 level being a significant resistance barrier. "

More news about USD/CNH (USDCNH).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com